Cargando…

Improved survival without increased toxicity with influenza vaccination in cancer patients treated with checkpoint inhibitors

In international guidelines, influenza vaccination is recommended to cancer patients receiving antitumor treatment. Whether this recommendation should include patients treated with the recently introduced and now widely used checkpoint inhibitors (CPIs) is unclear. The immune hyperactivation after v...

Descripción completa

Detalles Bibliográficos
Autores principales:	Valachis, Antonios, Rosén, Camilla, Koliadi, Anthoula, Digkas, Evangelos, Gustavsson, Alice, Nearchou, Andreas, Ullenhag, Gustav J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7894446/ https://www.ncbi.nlm.nih.gov/pubmed/33643697 http://dx.doi.org/10.1080/2162402X.2021.1886725

Ejemplares similares

Predicting immune‐related adverse events using a simplified frailty score in cancer patients treated with checkpoint inhibitors: A retrospective cohort study
por: Olsson Ladjevardi, Cecilia, et al.
Publicado: (2023)

Randomized Versus Real-World Evidence on the Efficacy and Toxicity of Checkpoint Inhibitors in Cancer in Patients with Advanced Non-small Cell Lung Cancer or Melanoma: A Meta-analysis
por: Digkas, Evangelos, et al.
Publicado: (2022)

Influenza vaccination in breast cancer patients during subcutaneous trastuzumab in adjuvant setting
por: Joona, Therse Björkin, et al.
Publicado: (2020)

Complete response with combined BRAF and MEK inhibition in BRAF mutated advanced low-grade serous ovarian carcinoma
por: Tholander, Bengt, et al.
Publicado: (2020)

Immune priming using DC- and T cell-targeting gene therapy sensitizes both treated and distant B16 tumors to checkpoint inhibition
por: Wenthe, Jessica, et al.
Publicado: (2022)

Toxicity, Response and Survival in Older Patients with Metastatic Melanoma Treated with Checkpoint Inhibitors †
por: de Glas, Nienke A., et al.
Publicado: (2021)

Cancer treatment of today in view of the Nobel Prize
por: Ullenhag, Gustav
Publicado: (2018)

Effect of Smoking on Treatment Efficacy and Toxicity in Patients with Cancer: A Systematic Review and Meta-Analysis
por: Bergman, Marie, et al.
Publicado: (2022)

Predicting toxicity caused by high-dose-rate brachytherapy single boost for prostate cancer
por: Olsén, Johan Staby, et al.
Publicado: (2022)

Quality of Life in the First Year of Follow-Up in a Randomized Multicenter Trial Assessing the Role of Imaging after Radical Surgery of Stage IIB-C and III Cutaneous Melanoma (TRIM Study)
por: Naeser, Ylva, et al.
Publicado: (2022)

Whole-body MRI including diffusion-weighted imaging compared to CT for staging of malignant melanoma
por: Mosavi, Firas, et al.
Publicado: (2013)

Improved Survival of Leukemic Mice Treated with Sodium Caseinate in Combination with Daunorubicin without Toxicity
por: Aguiñiga-Sánchez, Itzen, et al.
Publicado: (2021)

Survival after introduction of adjuvant treatment in stage III melanoma: a nationwide registry-based study
por: Helgadottir, Hildur, et al.
Publicado: (2023)

A Phase I Dose-Escalation Study of Lenalidomide in Combination with Gemcitabine in Patients with Advanced Pancreatic Cancer
por: Ullenhag, Gustav J., et al.
Publicado: (2015)

Optimizing antiresorptive treatment in patients with bone metastases: time to initiation, switching strategies, and treatment duration
por: Mjelstad, AnneMarthe, et al.
Publicado: (2019)

How we treat neurological toxicity from immune checkpoint inhibitors
por: Spain, Lavinia, et al.
Publicado: (2019)

Complete and long-lasting clinical responses in immune checkpoint inhibitor-resistant, metastasized melanoma treated with adoptive T cell transfer combined with DC vaccination
por: Lövgren, Tanja, et al.
Publicado: (2020)

Expression patterns and prognostic implications of tumor-infiltrating lymphocytes dynamics in early breast cancer patients receiving neoadjuvant therapy: A systematic review and meta-analysis
por: Zhu, Yajing, et al.
Publicado: (2022)

Older meningioma patients: a retrospective population-based study of risk factors for morbidity and mortality after neurosurgery
por: Löfgren, David, et al.
Publicado: (2022)

Risk for morbidity and mortality after neurosurgery in older patients with high grade gliomas – a retrospective population based study
por: Löfgren, David, et al.
Publicado: (2022)

How we identify and treat neuromuscular toxicity induced by immune checkpoint inhibitors
por: Jordan, B., et al.
Publicado: (2021)

Endocrine Toxicity and Outcomes in Patients With Metastatic Malignancies Treated With Immune Checkpoint Inhibitors
por: Al Ashi, Suleiman I, et al.
Publicado: (2021)

Association of DNA repair gene variants with colorectal cancer: risk, toxicity, and survival
por: Salimzadeh, Hamideh, et al.
Publicado: (2020)

Gastrointestinal Toxicities of Immune Checkpoint Inhibitors Are Associated With Enhanced Tumor Responsiveness and Improved Survival
por: Alomari, Mohammad, et al.
Publicado: (2022)

Immune Checkpoint Inhibitors and the Exposome: Host-Extrinsic Factors Determine Response, Survival, and Toxicity
por: Pizzutilo, Elio Gregory, et al.
Publicado: (2023)

Translational Medicine and Reliability of Single-Nucleotide Polymorphism Studies: Can We Believe in SNP Reports or Not?
por: Valachis, Antonis, et al.
Publicado: (2011)

Baseline antibody profiles predict toxicity in melanoma patients treated with immune checkpoint inhibitors
por: Gowen, Michael F., et al.
Publicado: (2018)

Gemcitabine reduces MDSCs, tregs and TGFβ-1 while restoring the teff/treg ratio in patients with pancreatic cancer
por: Eriksson, Emma, et al.
Publicado: (2016)

De novo metastatic breast cancer in men vs women: a Swedish population-based cohort study
por: Schiza, Aglaia, et al.
Publicado: (2023)

Discordance of PIK3CA mutational status between primary and metastatic breast cancer: a systematic review and meta-analysis
por: Rosin, Justus, et al.
Publicado: (2023)

Case report: A case of duodenal adenocarcinoma achieving significantly long survival treating with immune checkpoint inhibitors and chemotherapy without positive biomarkers
por: Chen, Xian, et al.
Publicado: (2022)

Management of Immune Checkpoint Inhibitor Toxicities
por: Durrechou, Quentin, et al.
Publicado: (2020)

Toxicities associated with checkpoint inhibitors—an overview
por: Spiers, Laura, et al.
Publicado: (2019)

Clinical and Immune Effects of Lenalidomide in Combination with Gemcitabine in Patients with Advanced Pancreatic Cancer
por: Ullenhag, Gustav J., et al.
Publicado: (2017)

Chemokine Analysis in Patients with Metastatic Uveal Melanoma Suggests a Role for CCL21 Signaling in Combined Epigenetic Therapy and Checkpoint Immunotherapy
por: Sah, Vasu R., et al.
Publicado: (2023)

Clinical and Molecular Characteristics Associated with Survival in Advanced Melanoma Treated with Checkpoint Inhibitors
por: Badami, Sunil, et al.
Publicado: (2018)

Predictors of Response and Survival in Immune Checkpoint Inhibitor-Treated Unresectable Hepatocellular Carcinoma
por: Lee, Pei-Chang, et al.
Publicado: (2020)

Associations between dysbiosis-inducing drugs, overall survival and tumor response in patients treated with immune checkpoint inhibitors
por: Gaucher, Louis, et al.
Publicado: (2021)

The role of immune checkpoint inhibitors in clinical practice: an analysis of the treatment patterns, survival and toxicity rates by sex
por: Wahli, Murielle N., et al.
Publicado: (2022)

Self-harm in Young People: Investigating the Role of Resilience and Posttraumatic Stress Related to the COVID-19 Pandemic
por: Nearchou, Finiki
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_v3h5alnh3ld8vde3uecuenrecl